The 43 references in paper A. Komarov L., А. КОМАРОВ Л. (2015) “ОЦЕНКА ЧУВСТВИТЕЛЬНОСТИ К КЛОПИДОГРЕЛУ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ // EVALUATION OF SENSITIVITY TO CLOPIDOGREL: THE CURRENT STATE OF THE PROBLEM” / spz:neicon:aterotromboz:y:2015:i:2:p:95-106

1
Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ. Рекомендации ВНОК. Ред. Руда М.Я. Кардиоваскулярная терапия и профилактика, Приложение 1, 2007, 6(8): 415–500.
(check this in PDF content)
2
Национальные рекомендации по лечению ОКС без стойкого подъема ST на ЭКГ Рекомендации ВНОК. Ред. Грацианский Н.А. Кардиоваскулярная терапия и профилактика, Приложение 1, 2006, 5: 411–440.
(check this in PDF content)
3
Национальные рекомендации по антитромботической терапии у больных со стабильными проявлениями атеротромбоза. Кардиоваскулярная терапия и профилактика, Приложение 6, 2009, 8(6).
(check this in PDF content)
4
2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal doi:10.1093/eurheartj/ehu278.
(check this in PDF content)
5
2013 ACCF/AHA Guideline for the Management of STElevation Myocardial Infarction. JACC,61, 4: 78–140.
(check this in PDF content)
6
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, Volume 64, Issue 24, e139–e228.
(check this in PDF content)
7
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33: 2569–2619 doi:10.1093/eurheartj/ehs215.
(check this in PDF content)
8
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation European Heart Journal doi:10.1093/eurheartj/ehv320.
(check this in PDF content)
9
Aradi D, Storey RF, Komocsi A et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 2014, 35, 209–215 doi:10.1093/eurheartj/eht375.
(check this in PDF content)
10
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Supplementary material. http://eurheartj.oxfordjournals.org/content/ehj/suppl/20 13/08/23/eht375.DC1/eht375supp.pdf.
(check this in PDF content)
11
Udaya S Tantry, Laurent Bonello, Daniel Aradi, for the Working Group on On-Treatment Platelet Reactivity. Consensus and Update on the Definition of OnTreatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. J Am Coll Cardiol, 2013, 62: 2261–73.
(check this in PDF content)
12
Stone GW, Witzenbichler B, Weisz G et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, 2013, 382: 614–623.
(check this in PDF content)
13
Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol, 2006, 7, 48(9): 1742–50.
(check this in PDF content)
14
Buonamici P, Marcucci R, Migliorini A, Gensini G, Santini A, Paniccia R, Moschi G, Gori A, Abbate R, Antoniucci D. Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis. J Am Coll Cardiol,2007, 49: 2312–7.
(check this in PDF content)
15
Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J, 2007, Aug. 154(2): 221–31.
(check this in PDF content)
16
Aradi D, Collet J, Mair J et al. Platelet function testing in acute cardiac care — is there a role for prediction or prevention of stent thrombosis and bleeding? Thromb Haemost, 2015, 113: 221–230.
(check this in PDF content)
17
Hulot J, Collet J, Silvain J et al. Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration: A Systematic Meta-Analysis.J Am Coll Cardiol,2010, Jul 6, 56(2): 134-43. doi: 10.1016/j.jacc.2009.12.071.
(check this in PDF content)
18
Stockbridge N. FDA Letter of Approval: May 5, 2009, NDA 20-839/S-040. U.S. Food and Drug Administration. URL: http://www.accessdata.fda.gov/ drugsatfda_docs/appletter/2009/020839 s040ltr.pdf. Accessed April 29, 2010.
(check this in PDF content)
19
Sarno G, Lagerqvist B, Nilsson J et al. Stent Thrombosis in New-Generation Drug-Eluting Stents in Patients With способно оказать влияние на дальнейший выбор лечения (табл. 3). Высокая ОРТ к АДФ и/или носительство аллельных вариантов низкой активности CYP2C19* могут свидетельствовать об ослабленном действии клопидогрела. В случае высокого риска ишемических событий у таких больных при отсутствии противопоказаний предлагается замена клопидогрела на более активные препараты — празугрел или тикагрелор. Увеличение дозы клопидогрела в этих случаях менее целесообразно. Адекватное подавление ОРТ к АДФ/нормальный генотип CYP2C19* предполагает отсутствие нарушений фармакодинамики клопидогрела. При относительно невысоком риске ишемических событий и/или высоком риске кровотечен
(check this in PDF content)
20
Loh JP, Torguson R, Pendyala LK et al. Impact of Early Versus Late Clopidogrel Discontinuation on Stent Thrombosis Following Percutaneous Coronary Intervention With First- and Second-Generation DrugEluting Stents. Am J Cardiol,2014, 113: 1968—1976.
(check this in PDF content)
21
Stone GW, Maehara A, Lansky AJ et al. A Prospective Natural-History Study of Coronary Atherosclerosis. N Engl J Med,2011, 364: 226–35.
(check this in PDF content)
22
Xie Y, Mintz GS, Yang J et al. Clinical Outcome of Nonculprit Plaque Ruptures in Patients With Acute Coronary Syndrome in the PROSPECT Study. J Am Coll Cardiol Img,2014, 7: 397–405.
(check this in PDF content)
23
Mauri L, Kereiakes DJ, Yeh RW. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med, 2014, 371: 2155–66.
(check this in PDF content)
24
Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. DOI: 10.1056/NEJMoa1500857.
(check this in PDF content)
25
Aradi D, Komуcsi A, Price MJ et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol,2013. Sep 1. 167(5): 2140–8. doi: 10.1016/j.ijcard.2012.05.100.
(check this in PDF content)
26
Комаров А.Л., Панченко Е.П., Донников А.Е., Шахматова О.О., Джалилова Г.В., Илющенко Т.А. Факторы, определяющие клиническую эффективность клопидогрела и прогноз у больных стабильной формой ишемической болезни сердца. Кардиология,2011, 2: 8-18.
(check this in PDF content)
27
Price MJ, Berger PB, Teirstein PS et al. Standard- vs highdose clopidogrel based on platelet function testing after percutaneouscoronary intervention: the GRAVITAS randomized trial. JAMA, 2011. Mar 16, 305(11): 1097-105. doi: 10.1001/jama.2011. 290.
(check this in PDF content)
28
Price MJ, Angiolillo DJ, Teirstein PS et al. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial. Circulation,2011, 124: 1132–1137.
(check this in PDF content)
29
Collet JP, Cuisset T, RangО G, et al for the ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med, 2012, 367: 2100–9.
(check this in PDF content)
30
Parodi G, Marcucci R, Valenti R et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. J Am Med Assoc, 2011, 306: 1215–1223.
(check this in PDF content)
31
Aradi D, Tornyos A, Pinter T et al. Optimizing P2Y-receptor inhibition in acute coronary syndrome patients based on platelet function testing: impact of prasugrel and highdose clopidogrel. J Am Coll Cardiol, 2014, Mar 25, 63(11): 1061–70. doi: 10.1016/j.jacc.2013.12.023.
(check this in PDF content)
32
Mayer K, Schulz S, Bernlochner I et al. A comparative cohort study on personalized antiplatelet therapy in PCItreated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thromb Haemost, 2014, 112: 342–351.
(check this in PDF content)
33
Siller-Matula JM, Francesconi M, Dechant C et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol, 2013. 167: 2018–2023.
(check this in PDF content)
34
Price MJ, Murray SS, Angiolillo DJ, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol,2012, May 29, 59(22): 1928–37.
(check this in PDF content)
35
Гуськова Е.В., Панченко Е.П., Комаров А.Л., Добровольский А.Б., Самко А.Н. Остаточная реактивность тромбоцитов к АДФ и риск кровотечений у больных стабильной ИБС, получающих двойную антитромбоцитарную терапию в связи с плановым чрескожным коронарным вмешательством.
(check this in PDF content)
36
Mega JL, Hochholzer W, Frelinger AL et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA, 2011, 306(20): 2221–2228.
(check this in PDF content)
37
Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med, 2009, 361.
(check this in PDF content)
38
Karve AM, Seth M, Sharma M. Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am J Cardiol, 2015. Jun 1.и 115(11): 1502-6. doi: 10.1016/j.amjcard. 2015.02.049.
(check this in PDF content)
39
Damman P, Varenhorst C, Koul S et al. Treatment Patterns and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Treated With Prasugrel or Clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). Am J Cardiol, 2014, 113: 64e69.
(check this in PDF content)
40
Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. http:// acc.sagepub.com/content/early/2014/11/20/2048872614560505.
(check this in PDF content)
41
S Gandhi, B Zile, M K. Tan. Increased Uptake of Guideline Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. Canadian Journal of Cardiology, 2014. doi: 10.1016/j.cjca. 2014.09.011.
(check this in PDF content)
42
Эрлих А.Д., Мацкеплишвили С.Т., Грацианскии Н.А., Бузиашвили Ю.И. и все участники московского регистра ОКС. Первыи московскии регистр острого коронарного синдрома: характеристика больных, лечение и исходы за время пребывания в стационаре. Кардиология, 2013, 12: 4–13.
(check this in PDF content)
43
Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in
(check this in PDF content)